Edison

Tenna Integrates with Fleet Cost & Care to Allow Contractors to Share Equipment Data and Optimize Maintenance

Retrieved on: 
Thursday, December 9, 2021

"Tenna's integration with Fleet Cost & Care is a golden opportunity for contractors in the crane industry to do just that while advancing their equipment management maturity to the next level."

Key Points: 
  • "Tenna's integration with Fleet Cost & Care is a golden opportunity for contractors in the crane industry to do just that while advancing their equipment management maturity to the next level."
  • The flow of OEM telematic data for the integration is AEMP-based, with Tenna's equipment information supporting the maintenance aspects of an asset within the Fleet Cost & Care software.
  • "The Tenna integration with Fleet Cost & Care will further our efforts in partnering with leaders in construction technology and asset tracking software.
  • Founded in 1993, Fleet Cost & Care (FCC) is a fleet management software company serving the heavy equipment industry around the globe.

StrikeForce Announces the Industry’s Most Secure Video Conferencing API is Now Available

Retrieved on: 
Tuesday, December 7, 2021

Our SafeVchat Secure Conferencing API enables businesses of all sizes the ability to easily integrate cyber security & video conferencing into any type of business application such as CRMs, Marketing platforms, Insurance & Healthcare applications or even Home-Grown Customer Support applications.

Key Points: 
  • Our SafeVchat Secure Conferencing API enables businesses of all sizes the ability to easily integrate cyber security & video conferencing into any type of business application such as CRMs, Marketing platforms, Insurance & Healthcare applications or even Home-Grown Customer Support applications.
  • Thats why several of our customers have chosen to integrate our SafeVchat Secure API into their platform(s), says Kay.
  • Most general-purpose video conferencing APIs typically treat all meetings the same way, from employee virtual happy hours to in-depth discussions of mergers and acquisition targets.
  • The API launch is not the only exciting news going on at StrikeForce right now, says George Waller, EVP.

CEO of Eos Energy Enterprises Applauds House Action and Supports Swift Passage of the Build Back Better Act in the Senate to Jumpstart Domestic Manufacturing

Retrieved on: 
Thursday, December 2, 2021

This is a once-in-a-generation moment for America to lock in the jobs that are going to be created in the renewable energy field.

Key Points: 
  • This is a once-in-a-generation moment for America to lock in the jobs that are going to be created in the renewable energy field.
  • For the first time since the 1990s, Congress is considering legislation that will incentivize companies to produce this new technology in America, not overseas.
  • The policies in the Build Back Better Act provide a level playing field to compete by prioritizing domestic manufacturing and encouraging innovation.
  • Eos Energy Enterprises, Inc. is accelerating the shift to clean energy with positively ingenious solutions that transform how the world stores power.

OpenBots Acquires araZach Healthcare-Salesforce Solutions Provider

Retrieved on: 
Thursday, December 2, 2021

OpenBots, Inc. (OB) , the world's leading zero-friction RPA and workflow automation platform, announces its acquisition of araZach LLC, a healthcare, life sciences, and Salesforce solutions provider.

Key Points: 
  • OpenBots, Inc. (OB) , the world's leading zero-friction RPA and workflow automation platform, announces its acquisition of araZach LLC, a healthcare, life sciences, and Salesforce solutions provider.
  • The araZach team has been solving "interoperability" problems within the healthcare industry using the OpenBots RPA platform extensively to build up its botConnector solution.
  • "Together, OpenBots and araZach will accelerate our customers' transformations into the age of automation, enabling them to grow their RPA programs more profitably," he continued.
  • For organizations where cloud adoption is a challenge due to enterprise security issues, OpenBots offers on-prem orchestration solutions with OpenBots Server .

Hepion Pharmaceuticals Receives FDA Fast Track Designation for CRV431 for the Treatment of NASH

Retrieved on: 
Tuesday, November 30, 2021

The FDA Fast Track designation allows sponsors to gain access to expedited drug approval reviews for medical conditions that are serious and potentially life-threatening, and where there is an unmet medical need.

Key Points: 
  • The FDA Fast Track designation allows sponsors to gain access to expedited drug approval reviews for medical conditions that are serious and potentially life-threatening, and where there is an unmet medical need.
  • We are now looking forward to initiating our larger Phase 2b NASH study, called ASCEND-NASH, in biopsy confirmed F2 and F3 NASH subjects in the coming months.
  • As such, we are very pleased to receive the FDAs Fast Track designation and are looking forward to working closely with the Agency as we advance development of CRV431.
  • Additionally, as part of the FDA Fast Track designation for CRV431 in NASH, Hepion will make its expanded access policy publicly available in the coming weeks.

Hepion Pharmaceuticals and FibroFind Announce Anti-Cancer Activity of CRV431 in a Nonclinical Liver Cancer Study

Retrieved on: 
Tuesday, November 16, 2021

The study was conducted by FibroFind Ltd. (Newcastle, UK) in collaboration with Professor Derek Mann, Dean of Research and Innovation at Newcastle University.

Key Points: 
  • The study was conducted by FibroFind Ltd. (Newcastle, UK) in collaboration with Professor Derek Mann, Dean of Research and Innovation at Newcastle University.
  • In this study, mouse hepatocellular cancer (HCC) cells (hep53.4 cells) were surgically implanted into livers of recipient mice.
  • Furthermore, CRV431 decreased the number of neutrophils in the tumors by 55%, which was not observed with anti-PD1 antibody treatment.
  • CRV431 targets the liver, and its anti-inflammatory and anti-fibrotic effects have been demonstrated in many liver disease models.

StrikeForce Shareholder Update

Retrieved on: 
Thursday, November 11, 2021

I am thrilled to provide this latest shareholder update, says Mark L. Kay, CEO, especially since we have accomplished so much since our last update which was only two months ago.

Key Points: 
  • I am thrilled to provide this latest shareholder update, says Mark L. Kay, CEO, especially since we have accomplished so much since our last update which was only two months ago.
  • Whats especially exciting is that we had limited marketing while we were waiting for our TV commercials to start.
  • StrikeForce Technologies helps to prevent Cyber theft and data security breaches for consumers, corporations, and government agencies.
  • StrikeForce Technologies, Inc. (OTCQB:SFOR) is headquartered in Edison, N.J., and can be reached at www.strikeforcetech.com or by phone at (732) 661-9641 or toll-free at (866) 787-4542.

Avaap Recognized as a Strong Workday Partner in KLAS First Look Report

Retrieved on: 
Thursday, November 11, 2021

COLUMBUS, Ohio, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Avaap, a Workday (NASDAQ:WDAY) services partner, today announced its recognition as a strong Workday Partner by KLAS in a new First Look report.

Key Points: 
  • COLUMBUS, Ohio, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Avaap, a Workday (NASDAQ:WDAY) services partner, today announced its recognition as a strong Workday Partner by KLAS in a new First Look report.
  • The KLAS First Look report covers how Avaap is supporting Workday deployments and helping hospitals and health systems digitally transform and modernize operations through technology investments.
  • KLAS is a research and insights firm on a global mission to improve healthcare delivery by amplifying the provider's voice.
  • Avaap is a HIMSS Analytics certified, industry-focused management and technology consulting firm with experience in Workday, Tableau, Epic, and other applications.

Hepion Pharmaceuticals Announces Poster Details for the Upcoming AASLD The Liver Meeting® 2021

Retrieved on: 
Wednesday, November 10, 2021

The meeting platform with posters is now open and the e-poster is also available on the publications page of the Companys website.

Key Points: 
  • The meeting platform with posters is now open and the e-poster is also available on the publications page of the Companys website.
  • The Company's lead drug candidate, CRV431, is a potent inhibitor of cyclophilins, which are involved in many disease processes.
  • These forward-looking statements are based on Hepion Pharmaceuticals current expectations and actual results could differ materially.
  • Hepion Pharmaceuticals does not undertake an obligation to update or revise any forward-looking statement.

Anti-Cancer Mechanism of Hepion Pharmaceuticals’ CRV431 Highlighted in Scripps Research Institute Poster at AASLD, The Liver Meeting® 2021

Retrieved on: 
Wednesday, November 10, 2021

Cyclophilin inhibition utilizing therapeutic agents, including Hepions investigational drug candidate CRV431, have previously been shown to reduce tumor burdern in this model.

Key Points: 
  • Cyclophilin inhibition utilizing therapeutic agents, including Hepions investigational drug candidate CRV431, have previously been shown to reduce tumor burdern in this model.
  • CRV431 inhibits many of the iso-forms of cyclophilins, enzymes involved in key aspects of disease progression.
  • The Company's lead drug candidate, CRV431, is a potent inhibitor of cyclophilins, which are involved in many disease processes.
  • Hepion Pharmaceuticals does not undertake an obligation to update or revise any forward-looking statement.